ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Jan. 10, 2020)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report January 10, 2020, filed under Item 7.01, Regulation FD Disclosure. The company states that the company plans to discuss the information in the presentation attached as Exhibit 99.1 with third parties in San Francisco, California. The report says the furnishing of the presentation is not an admission as to the materiality of any information in it, and that the Item 7.01 information shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. Exhibit 99.1 is listed as a presentation dated January 2020. The signature block shows /s/ Joseph E. Payne, Chief Executive Officer, dated January 10, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event
reported): January 10, 2020

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified
in its charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive, Suite 250

San Diego, California 92121

(Address of principal executive offices)

Registrant’s telephone number,
including area code: (858) 900-2660

(Former name or former address, if changed
since last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Arcturus Therapeutics Holdings Inc. (the
“ Company ”) plans to discuss the information contained in the presentation attached to this Current Report on
Form 8-K as Exhibit 99.1 with third parties in San Francisco, California.

The furnishing of the attached presentation
is not an admission as to the materiality of any information therein. The information contained in the slides is summary information
that is intended to be considered in the context of more complete information included in the Company’s filings with the
SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The
Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from
time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents
with the SEC, through press releases or through other public disclosures. For important information about forward looking statements,
see the slide titled “Forward-looking Statements” in Exhibit 99.1 attached hereto.

The information in this Item 7.01
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18
of the Exchange Act, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act.
The information contained in this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current Report shall
not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof,
regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description of Exhibit
99.1 | Presentation dated January 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: January 10, 2020
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2020-01-10_0001193805-20-000030.htm

Size

16,993 bytes

SHA-256

ec360151744183416ab8b2f6818bfe5dab57bd49cb3db9f7ca50d1d8392f41b0

Our copy

SEC_ARCT_8-K_filed2020-01-10_0001193805-20-000030.htm

Original

www.sec.gov